NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA clearance by Health Canada for a phase 1/2a clinical trial in moderate Alzheimer’s Disease patients
Related news for (NKGN)
- NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations
- NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
- NKGen Biotech To Present on the Use of Troculeucel for Alzheimer’s and Parkinson’s Disease at the 7th China International Biotechnology Conference & Exhibition
- NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)
- NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)